Grifols (Grifols) Interest Expense

: $-411 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Grifols's interest expense for the three months ended in Dec. 2023 was $ -99 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-411 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Grifols's Operating Income for the three months ended in Dec. 2023 was $ 95 Mil. Grifols's Interest Expense for the three months ended in Dec. 2023 was $ -99 Mil. Grifols's Interest Coverage for the quarter that ended in Dec. 2023 was 0.95. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Grifols Interest Expense Historical Data

The historical data trend for Grifols's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-360.42

-271.19

-264.20

-470.91

-562.77

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Interest Expense																-113.69	-138.73	-151.00	-161.08	-99.24

Grifols Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-411 Mil.

Grifols (NAS:GRFS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Grifols's Interest Expense for the three months ended in Dec. 2023 was $-99 Mil. Its Operating Income for the three months ended in Dec. 2023 was $95 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $10,054 Mil.

Grifols's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	94.64	/	-99.243
	=	0.95

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Grifols SA interest coverage is 1.53, which is low.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.